Replies to post #3528 on Skye Bioscience Inc (SKYE)

[CopperHunter]

Heck ya! We are behind him! Let’s go

[TheMonolith]

All this for a $13M fully diluted market cap? Pfffffffffffffffffffffffft

[TheMonolith]

NMUS DD

Fully Diluted O/S around 53M shares!

NEMUS Bioscience, Inc. (OTC:NMUS) is pleased to announce that it has received the remaining $400,000 under the previously announced Bridge Loan with Emerald Health Sciences Inc. (“Emerald”)

https://www.dailymarijuanaobserver.com/single-post/2018/01/19/NMUS-Nemus-Receives-400000-Under-Bridge-Loan-and-Closes-Private-Placement

We greatly value the intellectual capital and discovery capacity of the University of Mississippi, with which Nemus has an exclusive agreement for novel cannabinoid technologies. We will work to support the business and developmental vision of our CEO, Dr. Murphy, across a spectrum of medical indications of unmet need. The Emerald Board believes that Nemus presents a significant value proposition for investors and we look forward to advancing its pipeline into clinical development.”

http://beta.latimes.com/nation/la-na-pot-monopoly-20140529-story.html

Emerald holds a majority of Nemus’ common shares on a deemed fully converted basis. Nemus’ current directors have resigned, except for Dr. Brian Murphy, who has been joined by Punit Dhillon and Jim Heppell as directors of the company. Mr. Dhillon and Mr. Heppell are also directors of Emerald.

http://emeraldhealth.ca/board-management/jim-heppell/#
http://emeraldhealth.ca/board-management/punit-dhillon/
http://emeraldhealth.ca/board-management/avtar-dhillon/

“We welcome Nemus into Emerald’s family of life science companies,” commented Dr. Avtar Dhillon, CEO and Chairman of Emerald’s Board of Directors.

Lift Cannabis Expo | Interview with Chris Wagner

Chris Wagner, CEO of Emerland Health Therapeutics, explains Emerald's work with scientists and researchers around the world plus the importance of standardization, dosing and delivery - and more!